Cargando…

Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir

Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a patient exhibiting severe hyperbilirubine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baba, Hayato, Tajiri, Kazuto, Nagata, Kohei, Kawai, Kengo, Minemura, Masami, Sugiyama, Toshiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2016
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965544/ https://www.ncbi.nlm.nih.gov/pubmed/27504082 http://dx.doi.org/10.1159/000447486

Ejemplares similares

Vanishing Tumor in a Liver Graft from a Hepatitis B Virus Surface Antigen-Positive Donor
por: Fuchino, Mayo, et al.
Publicado: (2017)

Successful Treatment for Chronic Hepatitis C-Autoimmune Hepatitis Overlap Syndrome due to Daclatasvir and Asunaprevir
por: Sugiura, Ayumi, et al.
Publicado: (2017)

A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
por: Tajiri, Kazuto, et al.
Publicado: (2013)

Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
por: de Ruiter, Petra E, et al.
Publicado: (2018)

The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
por: Taki, Shinya, et al.
Publicado: (2018)

Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients
por: Tarao, Kazuo, et al.
Publicado: (2017)

Peritumoral Hyperplasia in Hepatic Sclerosed Hemangioma
por: Shimada, Seitarou, et al.
Publicado: (2017)

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)

Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions
por: Fujii, Hideki, et al.
Publicado: (2017)

COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes
por: Said, Zeinab Nabil Ahmed, et al.
Publicado: (2023)

Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia
por: Takakusagi, Satoshi, et al.
Publicado: (2018)

Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions
por: Miyashima, Yuichi, et al.
Publicado: (2016)

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
por: Takakusagi, Satoshi, et al.
Publicado: (2021)

A Patient with Non-alcoholic Steatohepatitis Complicated by Multiple Myeloma
por: Akashi, Momoko, et al.
Publicado: (2018)

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016)

Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial
por: Ueda, Akira, et al.
Publicado: (2013)

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection
por: Otsuka, Taiga, et al.
Publicado: (2017)

Exposure‐Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection
por: Ueno, Takayo, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
por: Oh, Jae Young, et al.
Publicado: (2019)

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
por: Itakura, Jun, et al.
Publicado: (2016)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
por: Kawakubo, Megumi, et al.
Publicado: (2018)

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
por: Lee, Byung Seok, et al.
Publicado: (2019)

Daclatasvir and asunaprevir improves health‐related quality of life in Japanese patients infected with hepatitis C virus
por: Ikeda, Hiroki, et al.
Publicado: (2018)

Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection
por: Fujii, Hideki, et al.
Publicado: (2022)

Glycogen Hepatopathy: A Rare and Underrecognized Cause of Recurrent Transaminitis in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Kumar, Kishore, et al.
Publicado: (2018)

Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2019)

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b
por: Matsumoto, Nobuyuki, et al.
Publicado: (2016)

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
por: Canini, Laetitia, et al.
Publicado: (2017)

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
por: Kato, Keizo, et al.
Publicado: (2019)

An Epileptic Patient with Recurrent Hyperbilirubinemia Caused by Gilbert Syndrome
por: Zhang, Yaoyao, et al.
Publicado: (2020)

Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China
por: Lu, Yun, et al.
Publicado: (2018)

Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b
por: Chida, Takeshi, et al.
Publicado: (2018)

Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy
por: Uchida, Yoshihito, et al.
Publicado: (2018)

Hepatic Sinusoidal Obstruction Syndrome Induced by Non-transplant Chemotherapy for Non-Hodgkin Lymphoma
por: Sakumura, Miho, et al.
Publicado: (2017)

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
por: Cho, Byeong Wook, et al.
Publicado: (2017)

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir
por: Friborg, Jacques, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1rjsls3m6d3tg1rnphke6p10o1